

Research article

Open Access

KIT is required for hepatic function during mouse post-natal development

Laetitia Magnol¹, Marie-Clémence Chevallier¹, Valérie Nalesso¹,
Stéphanie Retif¹, Helmut Fuchs², Martina Klempt², Patricia Pereira¹,
Michel Riottot³, Sandra Andrzejewski⁴, Bich-Thuy Doan⁵, Jean-
Jacques Panthier⁶, Anne Puech⁴, Jean-Claude Beloeil⁵, Martin Hrabe de
Angelis² and Yann Héroult*¹

Address: ¹Institut de Transgénose, TAAM, UPS44, IEM UMR6218, CNRS, Université Orléans, rue de la Férollerie Orléans, France, ²GSF Research centre, Institute of Experimental Genetics, Ingolstaedter Landstrasse Neuherberg, Germany, ³NOPA, INRA-Université Paris Sud, Orsay, France, ⁴CNRG-CNG Evry, Rue G. Crémieux, Evry, France, ⁵CBM CNRS, Rue Charles-Sadron, Orléans, France and ⁶UMR955 INRA-ENVA Maisons-Alfort, Avenue du Général de Gaulle, Maisons-Alfort, France

Email: Laetitia Magnol - magnol@cnrs-orleans.fr; Marie-Clémence Chevallier - chevalli@cnrs-orleans.fr; Valérie Nalesso - nalesso@cnrs-orleans.fr; Stéphanie Retif - sleroux@cnrs-orleans.fr; Helmut Fuchs - hfuchs@gsf.de; Martina Klempt - Klempt@gsf.de; Patricia Pereira - lopes@cnrs-orleans.fr; Michel Riottot - Michel.Riottot@ibaic.u-psud.fr; Sandra Andrzejewski - sandra.andrzejewski@cng.fr; Bich-Thuy Doan - doan@cnrs-orleans.fr; Jean-Jacques Panthier - panthier@jouy.inra.fr; Anne Puech - anne.puech@cng.fr; Jean-Claude Beloeil - beloeil@cnrs-orleans.fr; Martin Hrabe de Angelis - hrabe@gsf.de; Yann Héroult* - herault@cnrs-orleans.fr

* Corresponding author

Published: 5 July 2007

Received: 17 December 2006

BMC Developmental Biology 2007, 7:81 doi:10.1186/1471-213X-7-81

Accepted: 5 July 2007

This article is available from: <http://www.biomedcentral.com/1471-213X/7/81>

© 2007 Magnol et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The *Kit* gene encodes a receptor tyrosine kinase involved in various biological processes including melanogenesis, hematopoiesis and gametogenesis in mice and human. A large number of *Kit* mutants has been described so far showing the pleiotropic phenotypes associated with partial loss-of-function of the gene. Hypomorphic mutations can induce a light coat color phenotype while complete lack of KIT function interferes with embryogenesis. Interestingly several intermediate hypomorphic mutations induced in addition growth retardation and post-natal mortality.

Results: In this report we investigated the post-natal role of *Kit* by using a panel of chemically-induced hypomorphic mutations recently isolated in the mouse. We found that, in addition to the classical phenotypes, mutations of *Kit* induced juvenile steatosis, associated with the downregulation of the three genes, *VldLR*, *Lpin1* and *Lpl*, controlling lipid metabolism in the post-natal liver. Hence, *Kit* loss-of-functions mimicked the inactivation of genes controlling the hepatic metabolism of triglycerides, the major source of energy from maternal milk, leading to growth and viability defects during neonatal development.

Conclusion: This is a first report involving KIT in the control of lipid metabolism in neonates and opening new perspectives for understanding juvenile steatosis. Moreover, it reinforces the role of *Kit* during development of the liver and underscores the caution that should be exerted in using KIT inhibitors during anti-cancer treatment.

Background

KIT is a well-known receptor tyrosine kinase controlling melanogenesis, hematopoiesis, gametogenesis, hearing, mast cells and the survival of Cajal cells from the intestine [1-7]. Furthermore Kit is expressed in several epithelial endothelium or endocrine cells but also in cholangiocytes during development and in the adult [8,9]. The binding of KITL, induces the dimerization of the KIT molecule, followed by a change in the configuration of the intracellular domain and the autophosphorylation of the receptor, opening several docking sites for signal transduction molecules containing SH2 binding domains. Hence the KIT signal is transduced by several pathways including that of the SRC family kinases, PLC- γ , Ras/MAPK, PI3K-AKT-mTor, JAK/STAT and also through the activation of the SNAI2 and MITF transcription factors [for review see [10-12]]. KIT belongs to the class III of the receptor tyrosine kinase family with CSF1R, PDGFR- α ,- β , KDR, FLT-1, -3 and -4, characterized by the presence of an autoinhibitory juxtamembrane (JM) domain. Without phosphorylation, the JM domain is inserted in between the N- and C-lobes blocking the DFG (Asp-Phe-Gly) conserved motif of the activation loop in an inactive conformation. Upon phosphorylation, changes in the conformation of the JM domain opens up the ATP binding site and repositions correctly the activation loop in the kinase domain [13,14]. Mutations that affect the activation loop are found in human mastocytose or leukemia, while deletions or insertions in the JM domain are observed in gastro intestinal tumor (GIST) and often correspond to gain-of-function [15]. The treatment of the *Kit*-induced tumors had taken a promising perspective with the use of STI-571 (Imatinib, Gleevec Novartis, Basel, Switzerland), that binds to the ATP-binding site, stabilizing the autoinhibitory structure with an inactive tyrosine kinase domain [14].

In human, *Kit* loss-of-function is linked to Piebald trait [16,17] and a large panel of mutations is reported [for a synthetic panel see [18]]. Similar pigmentation defects are observed in mouse models [2] and the analysis of KIT functions was facilitated by a large number of hypomorphic murine mutants [4,12]. Some correspond to point mutations, others to large chromosomal rearrangements obtained as spontaneous or induced by chemicals or radiation, while a few were engineered [2,8,19,20]. Complete lack of *Kit* interferes with post-natal viability [8] while hypomorphic mutations could induce not only a variable degree of defects during melanogenesis, hematopoiesis and gametogenesis but also growth retardation and juvenile mortality [4,18].

In this report we used a panel of mutants isolated from genome-wide mutagenesis screens to investigate the post-natal role of KIT. These mutations correspond to a new allelic series of hypomorphic *Kit* alleles that alter differen-

tially the melanogenesis, hematopoiesis and gametogenesis. In two such mutants, we observed an impaired viability of the homozygotes before weaning. Clearly, growth retardation and premature death of neonates in both *Kit* mutants were associated with juvenile steatosis during the suckling period. Further analysis pointed out that *Kit* is expressed in the post-natal liver and *Kit* mutants were suffering from an early defect in triglycerides (TG) export from the liver correlated with the downregulation of key genes participating in the control of hepatic lipid metabolism. This series of evidence established the major role of *Kit* in controlling liver triglycerides metabolism in neonates.

Results

Characterization of a new allelic series of mutants affecting the *Kit* gene

To analyze the role of *Kit* in neonates, we used new semi-dominant ENU-induced mutant mouse lines named *Sco1*, *Sco5* ("Spotted coat"), *Sow3* ("Sister of W") and *Whc1* ("White coat"), displaying white head blazes and belly spots, that were isolated in genome wide mutagenesis programs [21,22] (Figure 1A). The corresponding mutations were mapped on the mouse chromosome 5 near the *Kit* locus (Figure 1B; data not shown). With the sequencing of the *Kit* gene from the *Sco1*, *Sco5* and *Whc1* homozygotes, unique missense mutations were found in the intracellular tyrosine kinase domain that affect M623L for *Sco1*, V667A for *Sco5* and F809L for *Whc1* (Figure 1C-1D). These changes were absent in the original C3HeB/FeJ and other strains. No mutation was found in the exonic and the splice junction sequences of the *Kit* gene from the *Sow3* mouse mutant line, suggesting that *Sow3* affects the regulation of the *Kit* gene as described in other mouse mutants [19,23,24]. Nonetheless, a series of complementation assays with other known alleles including *Kit^W*, *Kit^{W-v}* and *Kit^{tm1Alf}* confirmed that *Kit* function was altered in *Sow3* (Figure 1E). Therefore, the data support that the mutants described here represent a new allelic series at the *Kit* locus, with three missense mutations (*Sco1*, *Sco5* and *Whc1*) and one probable mutation affecting the regulation of the *Kit* gene (*Sow3*).

Homozygous animals generated for the four mutations displayed similar white coat pigmentation with black eyes (Figure 1A). However, *Sco1* homozygotes showed a few grey hairs and pigmented ears suggesting that this allele alters later stages of pigmentation [25]. Blood analysis showed changes characteristic of macrocytic anemia, with a significant reduction of hematocrit and red blood cell count, together with an increase in mean red cell volume and in mean cell hemoglobin content for all the adult mutant mice (Figure 2A). Hematopoietic defects were more severe in the *Sco5* and *Whc1* homozygotes than in *Sow3* and *Sco1* mutants with however some little varia-




Figure 1

New ENU-induced alleles at the *Kit* locus. (A) Heterozygous individuals carrying the *Sco1*, *Sco5*, *Sow3* and *Whc1* mutations display white spotting on the belly and a white forehead blaze while homozygotes (-/-) have a white coat color with black eyes. (B) Haplotype analysis of 114 *Sow3*^{+/+} mutant mice derived from the F1 C3FeB6 × B6 strategy. Markers are shown with their position (Mb) from the centromere of chromosome 5 (position based on Ensembl v33) and the position of the *Kit* gene is shown by an arrowhead. The black and white boxes represent respectively the B6 and the C3Fe alleles. The cumulative number of mice sharing the same haploid genotype is noted at the top of each column. (C) The mutated amino-acids found in the *Sco1*, *Sco5* alleles are located in the N-terminal hinge part of the intracellular tyrosine kinase domain of the KIT protein, at the vicinity of the T660 amino acid, mutated in the *Kit*^{W-v} allele, whereas the F809 modified in *Whc1* is found at the level of the Mg²⁺ binding loop of the activation segment. (D) Sequence chromatograph spanning the *Sco1*, *Sco5* and *Whc1* mutation sites respectively in exons 12, 14 and 17 of the *Kit* gene compared with that of a wild-type control from the same genetic background (C3Fe). The amino-acid substitution is labeled in red. (E) Transheterozygous animals carrying the *Sow3* and the *Kit*^{W-v} or the *Kit*^W allele exhibit a white coat color and pigmented eyes.

tions between males and females. Finally, histological analysis of testis isolated from adult males homozygous for *Sco1*, *Sco5* and *Whc1* showed different stages of germ cells differentiation while *Sow3* homozygotes revealed a complete lack of spermatogenesis (Figure 2B). These results were confirmed by the absence of β -galactosidase staining in the seminiferous tubules of *Kit^{tm1Alf/Sow3}* transheterozygotes (Figure 2B) and assessed by a fertility test. Only the *Sco1* and *Sco5* homozygotes were able to reproduce but no progeny was ever obtained from crosses between *Sow3/Sow3* males and wild-type females (data not shown). Thus, *Sco1*, *Sco5*, *Sow3* and *Whc1* are hypomorphic mutations of *Kit*, with the expected effects, although variable, on melanogenesis, hematopoiesis and gametogenesis.

Sco5 mutant analysis unravels a function of Kit during post-natal development of the liver

An impaired viability affected *Kit^{Sco5}* homozygotes before weaning, with only 21 mutants recovered out of 241 offspring from *Kit^{Sco5/+}* intercrosses. Although *Sco5/Sco5* genotypes scored at birth with a Mendelian ratio, almost 50% of them died before 7.5 days post partum (dpp), and only 25% survived at weaning (Figure 3A). In addition, *Kit^{Sco5/Sco5}* homozygotes displayed a growth defect at 3.5 dpp, with a weight difference reaching up to 50% of the control at 21 dpp (Figure 3B). Comparable phenotypes were also noted in *Kit^{Whc1/Whc1}* and *Kit^{W/W-v}* animals, thus we analyzed further this post-natal lethal phenotype.

Necropsy analysis revealed that the liver from *Kit^{Sco5/Sco5}* animals at 7.5 dpp had a tan yellowish color (Figure 3C) although it had a normal relative organ weight (data not shown). Anemia was detected in mutants at this early age and could partly account for the liver color alteration. However, the spotted aspect and the presence of large white areas in the hepatic lobes in all *Kit^{Sco5/Sco5}* analyzed at 7.5 dpp ($n > 10$) were associated with an abnormal structure of hepatocytes (Figure 3D). Indeed, lipid microvesicular accumulation, or steatosis, was detected in mutant hepatocytes by specific staining at 7.5 and 10.5 dpp with Oil-red-O (Figure 3D). Similar lipid inclusions were observed in the liver of *Kit^{Whc1/Whc1}* neonates (data not shown), to a lesser extent in *Kit^{Sco5/+}* animals and also in few *Kit^{Sco5/Sco5}* individuals that survived until two months of age (Figure 3E). A comparable phenotype was detected in 7.5 dpp and adult *Kit^{W/W-v}* mice (Figure 3E). By contrast, *Kit^{Sow3}* and *Kit^{Sco1}* homozygotes developed normally and did not display any hepatic phenotype. Thus the liver phenotype was not specific to the *Sco5* allele of *Kit*, as it was also found in a number of compound *Kit* mutants.

Then, we investigated the onset of the phenotype by following the lipid/water ratio in the liver of newborn mice

using nuclear magnetic resonance spectroscopy (NMR). Accumulation of hepatic lipids in *Kit^{Sco5/Sco5}* mutants was detected at 2.5 dpp (Figure 3F) suggesting that defect started earlier. Moreover the lipid/water ratio increased until 8.5 dpp when most of the homozygotes begun to die (5 out of 8 studied) as predicted from the original analysis of viability. Nevertheless, the lipid/water ratio was still high in surviving mutants compared to controls at 10.5 dpp (Figure 3F). To further define the onset of the phenotype, liver sections from groups of mutants and control littermates ($n = 3$) were analyzed during post-natal development. No change was observed immediately after birth in neonates that had not yet suckled any milk (Figure 3G). However, microvesicular accumulations of lipids were found at 1.5 dpp in the liver of wild-type suckling animals from the C3HeB/FeJ, C57BL/6J and 129S2 inbred lines. In the *Sco5/Sco5* mutant, a similar accumulation of lipids appeared at 1.5 dpp but remained later on, showing that lipids, derived mainly from the milk, were efficiently absorbed by the intestine, transported in the blood but abnormally stored in the liver. The characterization of the hepatic lipid content revealed a dramatic increase of triglycerides with no variation in phospholipids but a slight decrease of the cholesterol in the liver of *Kit^{Sco5/Sco5}* mice at 7.5 and 10.5 dpp (Figure 4A). This hepatic accumulation was not followed by an increase of the concentration of plasma triglycerides as observed in obesity or in liver diseases (Figure 4B), but the mutant mice displayed lower concentrations of free and HDL cholesterol as well as LDL cholesterol at both ages. Thus, lipid transport in plasma and exchange between tissues were deficient or not yet mature in *Sco5/Sco5* suckling neonates, leading to the persistence of the steatosis at 2.5 dpp and later on. Therefore, these results suggest that the lethality induced by *Kit* hypomorphic alleles was concomitant with the impaired lipid metabolism observed in mutant animals during the suckling period.

Kit is expressed in the liver of neonates and adults

Consistent with the phenotype, *Kit* gene expression was detected during post-natal development in the liver by using the *lacZ* reporter gene inserted in the first exon of *Kit* from the *Kit^{tm1Alf/+}* mouse [8]. *Kit* expression was detected in a large number of cells in the liver from 0.5 to 2.5 dpp, as a reminiscence of fetal hematopoiesis (Figure 5A). Thereafter, *Kit* expression was confined to a few cells located in the hepatic parenchyma and was also found in the epithelial cells of the biliary canals at later stages and in adults. As expected, the number of *Kit⁺* cells was dramatically reduced at 0.5 dpp in moribund *Kit^{tm1Alf}* homozygotes [8]. In trans-heterozygotes *Kit^{tm1Alf/Sco5}* and *Kit^{tm1Alf/Sow3}*, a reduced number of *Kit⁺* cells were detected at 7.5 dpp while steatosis was observed (Figure 5B and data not shown). Thus, lipid accumulation was induced by several combinations of *Kit* mutations during the post-




Figure 2

Blood and germ cells phenotypes in mice homozygous for the *Sco1*, *Sco5* and *Sow3* alleles. (A) Specific parameters including Red Blood Cells (RBC), Hemoglobin (Hb), hematocrit (Hct), Mean Red Cell volume (MRCV), Mean Cell Haemoglobin Concentration (MCHC), Mean Cell Hemoglobin (MCH), Red Cell Distribution Width (RCDW), Platelet, Mean Platelet Volume (MPV) and White Blood Cells (WBC) were determined for homozygous males (*Sco1/Sco1*, n = 5; *Sow3/Sow3*, n = 11; *Sco5/Sco5*, n = 6; *Whc1/Whc1*, n = 6) and compared to wild-type (wt, n = 11) individuals. Results are expressed as mean ± sem. (B) Testis were sectioned and stained with Hematoxylin and Eosin showing a normal appearance and organization in the *Sco1* and *Sco5* mutants. On the contrary, the seminiferous tubules of *Sow3* adult mutant individuals are lacunar with a complete absence of all the layers corresponding to the differentiation of spermatogonial stem cells. The β -galactosidase pattern of expression reveals that *Kit^{tm1Alfl}/Sow3* mutant mice showed no pattern of spermatogenesis compared to *Kit^{tm1Alfl}/+*.

natal period and its appearance was clearly associated with a decrease in the number of KIT expressing cells in the liver.

Molecular characterisation of the *Kit*-induced steatosis during post-natal development

To decipher the molecular basis of *Kit*-dependent steatosis, we determined the expression profiles of key genes involved in lipid hepatic metabolism: such as apolipoproteins (*Apoa1*, *ApoB*), lipoprotein receptors (*LdlR*, *Vldlr*, *Scarb1*, *Lrp1*), lipase (*Lipc*, *LipH*, *Lpl*) and others implicated in hepatic lipidogenesis (*Scap*, *Srebf1*, *Srebf2*), lipid secretion (*Pltp*, *Mttf*, *Abca1*), bile acid synthesis (*Cyp8b1*,

Cyp7a1), lipid transport (*Slc10a1*, *Abcb11*, *Abcb1a*, *Abcc2*) and a lipodystrophy gene, *Lipin 1* (*Lpin1*), encoding a phosphatidate phosphatase enzyme with transcription activity [26-28]. Expression of most of the genes remained unchanged in wild-type and mutant individuals at 10.5 dpp (not shown) except for the very low density lipoprotein receptor (*Vldlr*), the *Lpin1* and the lipoprotein lipase (*Lpl*) genes that were downregulated in *Sco5/Sco5* mutants compared to wild-type littermates (Figure 6). In addition *Vldlr* expression appeared to be significantly retarded at 1.5 dpp just during the transient steatosis while the expression level reached a plateau at 2.5 dpp with the same expression level found at 10.5 dpp. The downregu-




Figure 3

Growth and liver defects in *Kit^{Sco5}* homozygotes during post-natal development. (A) Viability and (B) body weight curves of *Sco5/Sco5* individuals generated from heterozygous *Sco5*/+ intercrosses (*Sco5/Sco5* n = 13; *Sco5*/+ n = 28; wt n = 16) reveal that mutant homozygotes are strongly affected during post-natal development compared to control littermates. (C) At 7.5 dpc, livers of mutants have a more yellowish color which was associated with the appearance of some white areas (white arrowhead). These alterations were never observed in wild-type (wt) littermates. (D) Hematoxylin and eosin, and Oil-red-O stainings reveal the swelling of hepatocytes with formation of large lipid-containing vesicles in *Sco5* homozygotes versus wild-type mouse littermates at 7.5 and 10.5 dpp (magnification ×40). (E) Staining of *Sco5*/+ individuals at 7.5 dpp shows a relative increase in lipid droplets inside hepatocytes compared to wild-type (D). A similar defect is observed in the liver of 7.5 dpp old mice, surviving adult *Sco5* homozygotes and *W/W-v* compound *Kit* mutants. (F) The lipid accumulation in the liver was studied by NMR during post-natal development at various ages on wt (n = 5; black) and mutant (n = 9,8,8,3; white) individuals. No statistical analysis was possible at 10.5 dpp because of the death of 6 mutants out of 9 (#), but the lipid/water ratio is still increased in mutant mice, at 10.5 dpp, in coherence with mortality scale and histology. (G) At 0.5 dpp, the Oil-red-O staining of liver sections from *Sco5* homozygous and control mice which had not yet suckled, are identical showing no accumulation of lipids. However, after breast feeding, hepatocytes from control newborns appear to stock lipids inside microvesicles at 1.5 dpp, a phenomenon that is not observed at later stages. On the contrary, in mutant mice which have suckled milk from their mother, lipids accumulation is still found in hepatic cells after 1.5 dpp.




Figure 4
Quantification of lipids in the liver and plasma of *Sco5/Sco5* mutants. Lipids were quantified from the liver (**A**; 5 individuals per genotype) and from the plasma (**B**; 10 individuals per genotype) of mutant and wild-type littermates at 7.5 and 10.5 dpp. Concentrations are indicated as a mean \pm s.e.m and expressed as mg/g of tissue or mg/dl respectively. PL, CH, TG for plasma lipids, cholesterol, triglycerides. HDL-C and LDL-C for cholesterol associated respectively with HDL and LDL.




Figure 5
Hepatic expression of *Kit* correlates with liver phenotype observed in several mutants during the post-natal development and in adult mice. (A) *Kit* expression was detected in the liver of *Kit^{tm1Alf/+}* mice by β -galactosidase activity on vibratome sections (40 \times) from 0.5 to 10.5 dpp, in adult, and on an eosin-stained sections (last panel). From birth to 2.5 dpp, β -galactosidase staining is found in a large number of hepatic cells, a reminiscence of the haematopoietic liver activity that takes place during late stage of embryonic development and ends after birth. As a consequence, the number of dispersed positive cells is reduced at 3.5 dpp. However, *Kit* expressing cells are clearly observed in the liver from 4.5 dpp to later stages and in adults. In *Kit^{tm1Alf/tm1Alf}* moribund newborns at 0.5 dpp, β -galactosidase staining is weaker due to the defect in hematopoiesis during fetal development but still remained in few cells. (B) At 7.5 dpp *lacZ* expression is detected in *Kit^{tm1Alf/+}* liver whereas no expression is observed in transheterozygous *Kit^{tm1Alf/Sco5}* and *Kit^{tm1Alf/Sow3}* liver. Such compound heterozygotes suffer from a strong lipid steatosis as shown here for *Kit^{tm1Alf/Sow3}* liver stained with oil-red-O (last panel). A similar staining was detected in *Kit^{tm1Alf/Sco5}* liver (not shown).

lation of *Lpin1* started to be detected at 1.5 dpp and was significant at 2.5 dpp when homozygote *Sco5* mutants suffer from the clearance of microvesicular accumulated lipids. Interestingly, the *Lpic* gene transcription is not significantly affected in the *Sco5* mutant at these ages. Altogether, these changes at the transcriptional level of key genes involved in hepatic lipid uptake (*VldLR*) or modification (*Lpin1*, *Lpl*) are helpful to understand the molecular mechanism of the *Kit*-induced defect in the liver.

Discussion

A new allelic series of *Kit* as a tool for deciphering downstream signaling pathways

In this paper, we described three new point mutations inducing loss-of-function of the KIT protein (*Sco1*, *Sco5* and *Whc1*) and one potential mutation affecting the regulation of the *Kit* gene (*Sow3*). Several other mutants affecting the level of *Kit* expression have been described in the literature [2,19,23,29], unraveling that quiet a few dispersed regulatory elements control *Kit* gene expression. Most of them correspond to large chromosomal rearrangement whereas *Sow3* is presumably a point mutation induced by ENU affecting a regulatory element control-




Figure 6
Misregulation of *Vldlr*, *Lpin1* and *Lpl*, in the liver of *Sco5* mutants compared to controls. At 2.5 dpp, a significant downregulation of *Lpin1* is observed in mutant (open rectangle) compare to wild type (filled rectangle) while *Vldlr* is significantly downregulated at 1.5 dpp. At 10.5 dpp, the expression level of *Vldlr*, *Lpin1* and *Lpl* is low in mutant compare to wild-type livers whereas the expression of *Lipc* is not affected. All the data were normalized as described in the Materials and Methods and were subjected to statistical analysis (Fischer and Student t tests, * for $p < 0.05$ and ** for $p < 0.01$).

ling *Kit* during melanogenesis and gametogenesis. The missense mutations described in *Sco1* and *Sco5*, at position M623 and V667 respectively, are found in the amino-terminal lobe near the ATP-binding site, whereas for *Whc1*, F809 is located in the DFG motif of the Mg^{2+} binding loop in the activation segment of the tyrosine kinase domain [14,30]. These residues are highly conserved in the KIT sequence deduced from various species, from human to zebrafish, and also in other mouse receptor tyrosine kinases from the same subfamily such as CSFR1, PDGFR, VEGFR, and FGFR (data not shown). Interest-

ingly, the two residues mutated in *Sco5* and *Sco1* are located in the amino-terminal lobe composed of β -strands, nearby the T660, that is mutated in the *W-v* allele, in the structure of the active KIT kinase [13] (Figure 1C). Overall the mutations described here are presumably hypomorphic because complete loss-of-function such as in the *lacZ* knock-in or in the *W* allele are homozygous lethal [8,31]. Of particular interest is the consequence of the F809L mutation located in the activation loop. This region of the tyrosine kinase domain undergoes a conformational change after the transphosphorylation of the autoinhibitory JM domain after KITL binding. Such a change will leave open the ATP-binding site and the Mg^{2+} binding loop for the receptor kinase activity. In addition, the anti-cancer drug STI-571 interacts notably with the F809 and blocks the tyrosine kinase domain in an inactive conformation [14]. Remarkably, the phenotypes observed in the *Whc1* homozygotes are similar to the *Sco5* allele with a strong impact on pigmentation and peripheral blood cells but not on germ cells. The four *Kit* mutants display pleiotropic phenotypes affecting with variable degrees the melanogenesis, hematopoiesis and gametogenesis in homozygotes. Interestingly, *Sco1*, *Sco5* and *Whc1* displayed essentially normal gametogenesis suggesting that the M623, V667 in the ATP binding site and the F809 in the activation loop domain are not as important as the Y719 bound by the phosphatidylinositol 3'-kinase (PI3K) that is essential for *Kit* function in testis [20]. Therefore the model of the inhibitory effect of the JM domain should be reconsidered for the germ cells to reconcile the absence of major germline defect in the *Whc1* mutant. These data stress out the complexity of the downstream signaling pathways and the targets that are controlled by the KIT protein in different organs.

The impaired viability of *Kit* mutants is associated with an altered hepatic lipid metabolism

Similar to the *Kit^{W/Wv}* and the *Kit^{Wads/Wads}* mutants recently described [18], the post-natal viability of the *Whc1* and of the *Sco5* homozygotes is strongly affected. Further detailed analysis identifies a major defect in hepatic lipid metabolism with steatosis at 7.5 dpp in animals carrying various combinations of hypomorphic *Kit* alleles, including *W/W-v*, *Sco5/lac*, *Sow3/lac*, *Sco5/Sco5* and *Whc1/Whc1*. Furthermore the appearance of steatosis is correlated with the defect in growth of the mutant initiated at 3.5 dpp. The determination of hepatic lipid content correlated the steatosis with a deregulated accumulation of TG just after suckling. During mammalian post-natal development, TG originate predominantly from the maternal milk and represent the major source of energy available for the neonates [32-34]. Ingested TG are assembled in chylomicrons particles and delivered to the developing organs. Following the local action of Lipoprotein Lipase (LPL), TG-derived free fatty acids (FFA) are absorbed by tissues

while the remaining of the chylomicrons, the remnants, is taken-up by the liver. During the fasting period, the liver participates in the uptake, oxidation, de novo synthesis, assembly and secretion of TG in very low density lipoproteins particules (VLDL; [35]. TG in VLDL are then used by the tissues depending on their LPL activity. The abnormal level of circulating LDL-C observed in *Kit* mutants suggests a defect in the liver to export and metabolize lipids from maternal milk. In addition, the maintenance of the "transient steatosis" state in the *Kit* mutants, observed in wild-type animals in the initial suckling phase just before the third post-natal day (this work; [36]. We suggest that the transient steatosis observed in wild-type animals corresponds to a transitory accumulation of lipids while the liver organ of neonates adapts its physiology to the triglyceride-rich regime of the suckling period. This was further supported by the expression analysis of genes such as *Vldlr* and *Lpin1* that start to be expressed at 2.5 dpp (this study). In *Kit* mutants, a defective hepatic metabolism, with the abnormal low expression of *Vldlr* and *Lpin1*, leads to the maintenance of this "transient steatosis".

Expression profiling for key genes participating to the metabolism, the transport, the modification, lipidogenesis and biliary acid synthesis in the liver revealed that only a few genes, namely *Vldlr*, *Lpin1* and *Lpl* were downregulated in *Kit* mutants. Consistent with the *Kit*-induced hepatic phenotype, interference with lipase function induces type I hyperlipoproteinemia in human (OMIN238600) and more severe hyperchylomicronemia affecting post-natal viability in *Lpl* mutant mice [37] or in *Combined Lipase deficiency (Cld)*, which alters both *Lpl* and Hepatic lipase (*Lipc*) activities [38-40]. In addition, VLDLR plays a major role in the metabolism of postprandial lipoproteins by enhancing LPL-mediated TG hydrolysis [41] and the *Vldlr* mutant mice suffer from growth retardation during the suckling period [37]. *Lpin1* reduced expression is presumably a major event leading to the abnormal metabolism of lipid in *Kit^{Sco5/Sco5}* mice. Indeed, *Lpin1* loss-of-function induces steatosis and juvenile lethality in the "fatty liver dystrophy" (*fld*) mice, a model of human lipodystrophy [27,42]. Recently, *Lpin1* has been shown to complement the phosphatidate phosphatase yeast deficiency [28]. In yeast its homolog regulates the level of triacylglycerol and FFA and represses the expression of genes involved in phospholipid synthesis. Similarly the hepatic fatty acid oxidation is reduced in *fld/fld* mice [43] and *Lpin1* is regulated by the transcription factor PGC-1 α that regulates several metabolic pathways. In addition LIPIN1 can activate the transcription of *Ppar α* and coactivates with PGC-1 α and PPAR α a large panel of other genes controlling lipid metabolism [44]. Therefore, downregulation of *Lpin1* in *Kit* mutants will lead to a reduced oxidation of lipids and steatosis in a context of increased lipid delivery during suckling. Similar to *fld/fld*

mice, some *Kit^{Sco5/Sco5}* animals could overcome steatosis after weaning but the most affected ones continued to display it. Consistent with our data, hyperlipidemia was observed in a fraction of adult *Kit^{W/W-v}* mice and correlated with an abnormal plasmatic lipoprotein profile and reduced lipolytic activities [45]. In addition to the *Lpin1* downregulation, repression of *Lpl* and *Vldlr* would also contribute to the hepatic *Kit*-induced phenotype. Interestingly, *Lpl* homozygous mutants died within 48 h after birth with severe hypertriglyceridemia [37]. Thus, linked to the steatosis observed in *Kit* hypomorphic mutants were changes in the expression of genes that are known to induce hepatic lipid metabolism anomalies in mutant mice. Such a change might explain why the hepatic deficiency is found in the surviving *Kit* homozygote adults. The absence of *Kit* expressing-cells and/or reduced *Kit* activity during development might have an indirect effect. In such a way, *Kit* loss-of-function mimicked the downregulation of *Lpin1*, *Lpl* and *Vldlr* leading to juvenile steatosis and growth retardation. Consistently, KIT and KITL were found to be expressed in the rat cholangiocytes [9] and several mouse mutants of *Kitl* displayed comparable low post-natal viability [46,47].

Involvement of the *Kit*-dependent steatosis and anemia in post-natal lethality

The origin of the post-natal deficiency observed in *Kit* mutants is commonly associated with anemia. The mutant post-natal phenotype is improved by the injection of mouse embryonic liver cells or bone marrow derived cells, 24 h after birth, respectively in 26% and 32% of *W/W-v* mutants [48]. The rescue is even better if the transplantation of embryonic liver cells is done through the placental circulation by day 11 of gestation [49]. Similarly the rescue of *Kit* mutant mice could be achieved by erythropoietin [50]. Interestingly in such rescue, the RBC counts and the percentage of homozygous mutants that survived the post-natal crisis are similar to our results confirming that another KIT-dependent factor influences the survival of the pups after birth. Thus we propose that the liver defect induced by *Kit* partial loss-of-function is one of these additional factors.

We described some molecular events affecting the neonatal hepatic function, but other changes in the liver of *Kit* mutants can not be ruled out. Additional analysis will help to describe in details the cellular mechanisms underlying the liver phenotype induced by *Kit* loss-of-function. Thus, even though *Kit*-induced anemia might participate to the post-natal crisis observed in the mutant mice, we propose that *Kit*-induced steatosis is a major factor at the origin of the post-natal mortality. Only a controlled inactivation of *Kit* in blood or liver compartments will help to clearly discriminate the impact of anemia and liver defect in the *Kit*-dependent impaired post-natal viability.

KIT and the signaling pathways controlling lipid metabolism in the liver

KIT is a receptor protein kinase controlling several signaling pathways. Some of them are known to control liver metabolism, such as the PI3K-AKT-mTOR, JAK/STAT [51,52], or to induce growth defect like for example in the *Snai2* mutant [12,53]. Thus another alternative to explain the importance of KIT in liver homeostasis could be due to the alteration of signaling pathways leading to impaired lipid metabolism. Alternatively, KIT could participate directly to the signaling pathway controlled by lipoprotein receptors. PDGFRB, another member of the same receptor family, is a co-receptor of the LDL receptor related protein [54,55]. Similarly, KIT could cooperate with members of the lipoprotein receptors family, such as VLDLR, or could control the expression of *Lpin1*, regulating the hepatic triglyceride metabolism and oxidative phosphorylation through its key position in the PPAR α /PGC-1 α regulatory pathway [44]. Interestingly, altering the binding of PI3K with the KIT protein, and reducing the activation of AKT to 10%, does not affect the weight of mutant animals [20], suggesting that, during the post-natal development, the KIT-dependent metabolism of triglycerides is not fully associated with the PI3K pathway but results from another signalling pathway.

Kit and the Fetal liver stem cells

KIT is a cellular marker of fetal liver stem cells, is involved in the differentiation/proliferation of the bipotent hepato-biliary progenitor cell [56,57]. In addition Kit expression is used to isolate population of hepatocytes during *in vitro* differentiation of ES cells [58]. Consistently, KITL is an important factor controlling hepatocyte proliferation after hepatectomy in IL6 mutant mice [59]. Thus, the steatosis could be an indirect consequence of a defect in the differentiation or the proliferation of hepatic progenitor cells leading to the loss of KIT⁺ cells observed in *Sco5/lac* or *Sow3/lac* animals. Decreasing the activity of KIT to a certain steatosis threshold will modify the pool of stem cells that will affect either the development of the liver and the post-natal hepatic homeostasis. Consequently, the defect in lipid metabolism of *Sco5/Sco5* adults might result from a consequence of a post-natal defect that was not compensated during the juvenile development. This hypothesis is in agreement with the pattern of expression of the genes tested. Kit expression is restricted in the juvenile and adult liver. Thus we should foresee an indirect effect of Kit on hepatocytes functions observed in this study.

Conclusion

Taken together, these data demonstrate the key function of *Kit* in neonates liver physiology and further explain the early hepatic defect induced by *Kit* loss-of-function. Now, KIT should be considered as one of the endogenous fac-

tors that could lead to steatosis [60]. A very low number of animal models are available to study the consequences of impaired lipid metabolism during suckling, reminiscent of some human conditions (OMIN 212140, 228100). These data open new perspectives for the molecular understanding of juvenile steatosis, the analysis of Kit function during liver development and support the need to follow-up hepatic function in patients during anti-cancer treatment with the inhibitor of KIT activity, STI-571, reported to affect the weight and the viability of rat neonates [61].

Methods

Mice

The *Sco1*, *Sco5*, *Sow3* mutant alleles were isolated from the chemical mutagenesis program ongoing in the Institute of Experimental Genetic at the GSF (Neuherberg, Germany) whereas the *Whc1* was recovered in a similar mutagenesis screen in Orleans. Investigations were achieved in the same genetic background C3HeB/FeJ (C3Fe) for the phenotypic analysis. Outcross and backcross on C57BL/6 (B6) were performed for the genetic mapping except for *Whc1* which was generated in a mixed C3Fe.B6 background. The B6 *Kit^W* and *Kit^{W-v}* alleles obtained from the TJL (Bar Harbor, Maine, USA) carry respectively a deletion of the transmembrane domain and a missense mutation at T660 M. The 129S2 *Kit^{tm1Alf}* mouse line corresponds to the disruption of the *Kit* gene sequence due to the insertion of a *lacZ* reporter gene in the first exon [8]. Standard diet (SDS) and water were provided ad libitum. All the mice were bred under SPF conditions and experiments were carried out according to the guidelines of the French Ministry of Agriculture for experiments with laboratory animals (law 87848 and YH accreditation 45-31).

Genetic and comparative gene sequence analysis

A panel of 60 MIT markers polymorphic between C3Fe and B6 was used for a genome-wide linkage analysis as described previously [21]. For complementation analysis, heterozygous mutant mice carrying the *Sco5*, *Sco1*, *Sow3* or the *Whc1* alleles were mated separately with *Kit^W*, *Kit^{W-v}* and *Kit^{tm1Alf}* heterozygous animals. Animals with a white coat color were classified as trans-heterozygous individuals.

For the sequence determination and the genomic DNA analysis, specific primer pairs were designed in the flanking sequences of each exon, except for the large exon 21, for which a series of overlapping PCR products were generated (Primer sequence available upon request). The amplicons generated from DNA isolated from two littermates corresponding to each phenotype (wild-type, heterozygous or homozygous mutants) were directly sequenced using the Big-dye terminator kit and analyzed on an ABI 310 automated sequencer. The nucleotide

changes noticed in *Sco1*, *Sco5* and *Whc1* alleles were confirmed to be specific to the mutant lines and not found in the founder strain C3HeB/Fe or C57BL/6J and others control strains including DBA, CBA, BALB/c, RIII/Dmob, RIIS/J, 129, A/J, AKR, PWK, IS/CamRk, IS/Cam Ei, PWD, Cast, NOD.

Phenotypic analysis

Groups of age- and sex-matched mutant and wild-type littermate mice were subjected to a series of tests following the recommendations from the standard operating procedures developed inside the EUMORPHIA network [62]. Several parameters were automatically scored for blood cell analysis by taking 100 μ l of blood from suborbital sinus of 6–8 week-old anaesthetized mice (isoflurane), collecting them in EDTA tubes (VWR) and running them through a Technicon H1 hematology analyser (BAYER). Fertility tests were carried out for a period of 4 months using 5 homozygous males mated with two wild-type females from the same genetic background. Females were checked for pregnancy every week and changed every two months.

For histological analysis, the liver was fixed overnight in Bouin's solution, embedded in paraffin wax and subjected to classical procedures for hematoxylin-eosin (H&E) staining. Frozen tissue sections were post-fixed with formalin solution (Accustain, Sigma) before staining with Oil-red-O (ORO) and hematoxylin. Sections were observed under a light microscope (Leica). For *lacZ* staining, sections of whole fresh liver were made on a vibratome or a cryotome (Leica) and post-fixed with 5% paraformaldehyde. The β -galactosidase activity was revealed using a standard procedure [63]. Pictures were taken with a Leica digital camera and processed with the Adobe Photoshop (v.7) software.

The *in vivo* NMR experiments were carried out on a 9.4 T horizontal imaging spectrometer (Bruker Biospec, USR, Wissembourg, France) equipped with a 950 mT/m gradient coil and a 20 mm inner diameter 1H custom made surface coil. The mice were anesthetized with 1% isoflurane (TEM, Bordeaux) and the animal's temperature and respiratory signal were controlled during anesthesia. After liver imaging, for spectroscopy, 1D 1H PRESS spectra were recorded on $2 \times 2 \times 2$ mm³ voxels located inside the liver (TR = 4 s, TE = 12 ms, na = 64, acquisition time = 6 min) after manual or semi automatic shimming. The total duration time was about 45 min per mouse. These spectra were used to quantify the lipids inside the liver compared with the water signal. The water and lipids peaks areas were integrated using the Xwinnmr Bruker software.

The lipid composition of the liver was evaluated using the method described in Boehler et al. [64]. Briefly, frozen liv-

ers were thawed and homogenized in propanol-2 using an ultra-turrax apparatus (Janke & Kunkel Gmb, Staufen, Germany). After incubation at 60°C for 1 h and centrifugation for 5 min at 3000 g, the supernatant was collected and the pellet was re-extracted with propanol-2. Phospholipids, triglycerides, and total cholesterol were measured enzymatically on the pooled propanolic extracts using appropriate kits: triglycerides PAP 150, phospholipids PAP 150 and Cholesterol RTU (Biomérieux S.A., 69280 Marcy l'étoile, France). Blood chemistry analysis was carried out with plasma isolated from Li-heparin-treated blood on an Olympus AU400 autoanalyzer (Olympus, Hamburg, Germany).

Expression analysis by quantitative RT-PCR

Total RNA was extracted from the liver using Trizol reagent (Life Technologies). Random hexamers were used for priming the first cDNA strand synthesis with 1 μ g of total RNA. We tested the expression of a panel of genes involved in hepatic lipid metabolism and known to be expressed in hepatocytes (*Ldlr*, *Lrp1*, [65], *ApoA1* [66], *ApoB* [67], *Cyp8b1*, *Cyp7a1* [68], *Abca1* [65], *Ntcp*, *Scap*, *Srebf1*, *Srebf2* [69,70]), in canicular membrane (*Abcb11*, *Abcb1a*, *Abcc2*, *Abcb4* [65,69,70]), in both cell type (*Scarb1* [71,72], *Abcb4* [65,69]), in Kupffer cells (*Lpl* [73]) or in a non specified hepatic area (*LipH* [74]; *Vldlr* [75], *Pltp* [76], *Mttp* [77], *Lipin1* [27]). The gene specific primer pairs for *Ldlr*, *Vldlr*, *ApoE*, *Lpdl*, *Lpin1*, *ApoB*, *Mttp*, *Abca1*, *Scap*, *Srebf1*, *Srebf2*, *Cyp7a1*, *Abcc2*, β -microglobulin were obtained from Quiagen (France) and the others from Primerbank [78]. They were used to amplify the specific transcripts from cDNA obtained from at least five different individuals, and quantified using Sybergreen on MX4000 apparatus (Stratagene, La Jolla, USA) using the 18S and β 2m RNAs as internal standards. Data were normalized for each gene using the $2^{-\Delta\Delta C_t}$ method in controls and *Sco5* homozygotes littermates (n > 5 at 10.5 dpp or n > 4 at 2.5 dpp per group) after standardization with the 18S rRNA and β 2-m mRNA.

Statistical analysis

All the results are expressed by the mean \pm s.e.m (standard error of the mean). Statistical analysis was carried using the Fischer's test and the Student's t-test and the null hypothesis was rejected for P < 0.05 unless otherwise indicated.

Abbreviations

ENU: N-Ethyl-N-NitrosoUrea

C3Fe: C3HeB/FeJ

B6: C57BL/6J

NMR: Nucleic Magnetic Resonance

Authors' contributions

LM conceived and performed most of the experiments and did the histological analysis for the *Sco5*, *Sco1* and *Sow3*. MCC collected the samples and did the QRT-PCR analysis on the liver of mutant and control mice. VN and SA generated the genetic mapping of the *Sco5*, *Sco1*, *Sow3* and *Whc1*. SR performed the post-natal survey and collected the samples for blood analysis. HF isolated and established the *Sco5*, *Sco1* and *Sow3* mutant lines MK did the blood chemistry analysis. PP analysed the samples from the *Whc1* mutant. MR performed the lipid analysis of the liver. BTD and JCB performed the MRI experiments. JJP collected the data for the expression analysis in the liver. AP controlled the Kit sequence polymorphism in several mouse lines. MH helped draft the manuscript. YH drafted the final manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Jean-Louis Guénet, Valérie Quesniaux, Véronique Brault, members of the laboratory for their helpful discussion and comments on the manuscript, Elodie Desale, Karine Vallon-Geoffroy and Candice Hackney for taking care of the animals, Angele Guilbot, M. Lathrop and colleagues from the CNG in Evry for their support and members of the Eumorphia consortium for their recommendations regarding the phenotype analysis. The mutant mice are available for distribution through the EMMA network ("European Mouse Mutant Archive"). This work was funded by grants from the French National Centre for Scientific Research (CNRS), the EURO-COMP (QLRI-CT1999-00877) and the EUMORPHIA projects (QLG2-CT-2002-00930) supported by the European commission under FP5.

References

- Geissler EN, McFarland EC, Russell ES: **Analysis of pleiotropism at the dominant white-spotting (W) locus of the house mouse: a description of ten new W alleles.** *Genetics* 1981, **97**:337-361.
- Geissler EN, Ryan MA, Housman DE: **The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene.** *Cell* 1988, **55**:185-192.
- Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A: **The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus.** *Nature* 1988, **335**:88-89.
- Besmer P, Manova K, Duttlinger R, Huang EJ, Packer A, Gyssler C, Bachvarova RF: **The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis.** *Dev Suppl* 1993:125-137.
- Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A: **W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity.** *Nature* 1995, **373**:347-349.
- Cable J, Jackson IJ, Steel KP: **Mutations at the W locus affect survival of neural crest-derived melanocytes in the mouse.** *Mech Dev* 1995, **50**:139-150.
- Cable J, Huszar D, Jaenisch R, Steel KP: **Effects of mutations at the W locus (c-kit) on inner ear pigmentation and function in the mouse.** *Pigment Cell Res* 1994, **7**:17-32.
- Bernex F, De Sepulveda P, Kress C, Elbaz C, Delouis C, Panthier JJ: **Spatial and temporal patterns of c-kit-expressing cells in WlacZ/+ and WlacZ/WlacZ mouse embryos.** *Development* 1996, **122**:3023-3033.
- Omori M, Everts RP, Omori N, Hu Z, Marsden ER, Thorgerirsson SS: **Expression of alpha-fetoprotein and stem cell factor/c-kit system in bile duct ligated young rats.** *Hepatology* 1997, **25**:1115-1122.
- Roskoski R Jr.: **Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.** *Biochem Biophys Res Commun* 2005, **338**:1307-1315.
- Ronnstrand L: **Signal transduction via the stem cell factor receptor/c-Kit.** *Cell Mol Life Sci* 2004, **61**:2535-2548.
- Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia A, Sanchez ML, Orfao A, Flores T, Sanchez-Garcia J: **Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway.** *Blood* 2002, **100**:1274-1286.
- Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, Sang BC, Nowakowski J, Kassel DB, Cronin CN, McRee DE: **Structure of a c-kit product complex reveals the basis for kinase transactivation.** *J Biol Chem* 2003, **278**:31461-31464.
- Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP: **Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.** *J Biol Chem* 2004, **279**:31655-31663.
- Longley BJ, Reguera MJ, Ma Y: **Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.** *Leuk Res* 2001, **25**:571-576.
- Fleischman RA, Saltman DL, Stastny V, Zneimer S: **Deletion of the c-kit protooncogene in the human developmental defect piebald trait.** *Proc Natl Acad Sci U S A* 1991, **88**:10885-10889.
- Spritz RA, Giebel LB, Holmes SA: **Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism.** *Am J Hum Genet* 1992, **50**:261-269.
- Ruan HB, Zhang N, Gao X: **Identification of a novel point mutation of mouse proto-oncogene c-kit through N-ethyl-N-nitrosourea mutagenesis.** *Genetics* 2005, **169**:819-831.
- Hough RB, Lengeling A, Bedian V, Lo C, Bucan M: **Rump white inversion in the mouse disrupts dipeptidyl aminopeptidase-like protein 6 and causes dysregulation of Kit expression.** *Proc Natl Acad Sci U S A* 1998, **95**:13800-13805.
- Blume-Jensen P, Jiang G, Hyman R, Lee KF, O'Gorman S, Hunter T: **Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility.** *Nat Genet* 2000, **24**:157-162.
- Besson V, Nalesso V, Herpin A, Bizot JC, Messaddeq N, Romand R, Puech A, Blanquet V, Herault Y: **Training and aging modulate the loss-of-balance phenotype observed in a new ENU-induced allele of Otopetrin1.** *Biol Cell* 2005, **97**:787-798.
- Hrabe de Angelis M, Strivens M: **Large-scale production of mouse phenotypes: the search for animal models for inherited diseases in humans.** *Brief Bioinform* 2001, **2**:170-180.
- Duttlinger R, Manova K, Berrozpe G, Chu TY, DeLeon V, Timokhina I, Chaganti RS, Zelenetz AD, Bachvarova RF, Besmer P: **The Wsh and Ph mutations affect the c-kit expression profile: c-kit misexpression in embryogenesis impairs melanogenesis in Wsh and Ph mutant mice.** *Proc Natl Acad Sci U S A* 1995, **92**:3754-3758.
- Kluppel M, Nagle DL, Bucan M, Bernstein A: **Long-range genomic rearrangements upstream of Kit dysregulate the developmental pattern of Kit expression in W57 and Wbanded mice and interfere with distinct steps in melanocyte development.** *Development* 1997, **124**:65-77.
- Wilson YM, Richards KL, Ford-Perriss ML, Panthier JJ, Murphy M: **Neural crest cell lineage segregation in the mouse neural tube.** *Development* 2004, **131**:6153-6162.
- Peterfy M, Phan J, Reue K: **Alternatively spliced lipin isoforms exhibit distinct expression pattern, subcellular localization, and role in adipogenesis.** *J Biol Chem* 2005, **280**:32883-32889.
- Peterfy M, Phan J, Xu P, Reue K: **Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin.** *Nat Genet* 2001, **27**:121-124.
- Han GS, Wu WI, Carman GM: **The Saccharomyces cerevisiae Lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme.** *J Biol Chem* 2006, **281**:9210-9218.
- Berrozpe G, Timokhina I, Yukl S, Tajima Y, Ono M, Zelenetz AD, Besmer P: **The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154 kb upstream of Kit.** *Blood* 1999, **94**:2658-2666.
- Nolen B, Taylor S, Ghosh G: **Regulation of protein kinases; controlling activity through activation segment conformation.** *Mol Cell* 2004, **15**:661-675.
- Bernstein A, Forrester L, Reith AD, Dubreuil P, Rottapel R: **The murine W/c-kit and Steel loci and the control of hematopoiesis.** *Semin Hematol* 1991, **28**:138-142.

32. Manson WG, Weaver LT: **Fat digestion in the neonate.** *Arch Dis Child Fetal Neonatal Ed* 1997, **76**:F206-11.
33. Stagers JE, Fernando-Warnakulasuriya GJ, Wells MA: **Studies on fat digestion, absorption, and transport in the suckling rat. II. Triacylglycerols: molecular species, stereospecific analysis, and specificity of hydrolysis by lingual lipase.** *J Lipid Res* 1981, **22**:675-679.
34. Fernando-Warnakulasuriya GJ, Stagers JE, Frost SC, Wells MA: **Studies on fat digestion, absorption, and transport in the suckling rat. I. Fatty acid composition and concentrations of major lipid components.** *J Lipid Res* 1981, **22**:668-674.
35. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA: **Hepatic Steatosis: A Mediator of the Metabolic Syndrome. Lessons From Animal Models.** *Arterioscler Thromb Vasc Biol* 2004, **24**:644-649.
36. Hughes DE, Stolz DB, Yu S, Tan Y, Reddy JK, Watkins SC, Diehl AM, Costa RH: **Elevated hepatocyte levels of the Forkhead box A2 (HNF-3beta) transcription factor cause postnatal steatosis and mitochondrial damage.** *Hepatology* 2003, **37**:1414-1424.
37. Weinstock PH, Bisgaier CL, Aalto-Setälä K, Radner H, Ramakrishnan R, Levak-Frank S, Essenburg AD, Zechner R, Breslow JL: **Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes.** *J Clin Invest* 1995, **96**:2555-2568.
38. Davis RC, Ben-Zeev O, Martin D, Doolittle MH: **Combined lipase deficiency in the mouse. Evidence of impaired lipase processing and secretion.** *J Biol Chem* 1990, **265**:17960-17966.
39. Hill JS, Davis RC, Yang D, Wen J, Philo JS, Poon PH, Phillips ML, Kempner ES, Wong H: **Human hepatic lipase subunit structure determination.** *J Biol Chem* 1996, **271**:22931-22936.
40. Boedeker JC, Doolittle MH, White AL: **Differential effect of combined lipase deficiency (cld/cld) on human hepatic lipase and lipoprotein lipase secretion.** *J Lipid Res* 2001, **42**:1858-1864.
41. Goudriaan JR, Espirito Santo SM, Voshol PJ, Teusink B, van Dijk KW, van Vlijmen BJ, Romijn JA, Havekes LM, Rensen PC: **The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis.** *J Lipid Res* 2004, **45**:1475-1481.
42. Langner CA, Birkenmeier EH, Ben-Zeev O, Schotz MC, Sweet HO, Davison MT, Gordon JL: **The fatty liver dystrophy (fld) mutation. A new mutant mouse with a developmental abnormality in triglyceride metabolism and associated tissue-specific defects in lipoprotein lipase and hepatic lipase activities.** *J Biol Chem* 1989, **264**:7994-8003.
43. Rehnmark S, Giometti CS, Slavin BG, Doolittle MH, Reue K: **The fatty liver dystrophy mutant mouse: microvesicular steatosis associated with altered expression levels of peroxisome proliferator-regulated proteins.** *J Lipid Res* 1998, **39**:2209-2217.
44. Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, Lawrence JC Jr., Kelly DP: **Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway.** *Cell Metab* 2006, **4**:199-210.
45. Hatanaka K, Tanishita H, Ishibashi-Ueda H, Yamamoto A: **Hyperlipidemia in mast cell-deficient W/WV mice.** *Biochim Biophys Acta* 1986, **878**:440-445.
46. Rajaraman S, Wood LK, Willhite DK, Russell LB, Bedell MA: **Effects of spontaneous KitlSteel mutations on survival and red blood cells of mice.** *Mamm Genome* 2003, **14**:168-174.
47. Rajaraman S, Davis WS, Mahakali-Zama A, Evans HK, Russell LB, Bedell MA: **An allelic series of mutations in the Kit ligand gene of mice. II. Effects of ethylnitrosourea-induced Kitl point mutations on survival and peripheral blood cells of Kitl(Steel) mice.** *Genetics* 2002, **162**:341-353.
48. Capel B, Hawley R, Covarrubias L, Hawley T, Mintz B: **Clonal contributions of small numbers of retrovirally marked hematopoietic stem cells engrafted in unirradiated neonatal W/Wv mice.** *Proc Natl Acad Sci U S A* 1989, **86**:4564-4568.
49. Fleischman RA, Mintz B: **Prevention of genetic anemias in mice by microinjection of normal hematopoietic stem cells into the fetal placenta.** *Proc Natl Acad Sci U S A* 1979, **76**:5736-5740.
50. Waskow C, Terszowski G, Costa C, Gassmann M, Rodewald HR: **Rescue of lethal c-KitW/W mice by erythropoietin.** *Blood* 2004, **104**:1688-1695.
51. Pang Q, Fagerlie S, Christianson TA, Keeble W, Faulkner G, Diaz J, Rathbun RK, Bagby GC: **The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by gamma interferon and hematopoietic growth factors.** *Mol Cell Biol* 2000, **20**:4724-4735.
52. Hadjir S, Ung K, Wadsworth L, Dimmick J, Rajcan-Separovic E, Scott RW, Buchwald M, Jirik FR: **Defective hematopoiesis and hepatic steatosis in mice with combined deficiencies of the genes encoding Fanc and Cu/Zn superoxide dismutase.** *Blood* 2001, **98**:1003-1011.
53. Jiang R, Lan Y, Norton CR, Sundberg JP, Gridley T: **The Slug gene is not essential for mesoderm or neural crest development in mice.** *Dev Biol* 1998, **198**:277-285.
54. Boucher P, Liu P, Gotthardt M, Hiesberger T, Anderson RG, Herz J: **Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low density lipoprotein receptor-related protein in caveolae.** *J Biol Chem* 2002, **277**:15507-15513.
55. Newton CS, Loukinova E, Mikhailenko I, Ranganathan S, Gao Y, Haudenschield C, Strickland DK: **Platelet-derived growth factor receptor-beta (PDGFR-beta) activation promotes its association with the low density lipoprotein receptor-related protein (LRP). Evidence for co-receptor function.** *J Biol Chem* 2005, **280**:27872-27878.
56. Nava S, Westgren M, Jaksch M, Tibell A, Broome U, Ericzon BG, Sumitran-Holgersson S: **Characterization of cells in the developing human liver.** *Differentiation* 2005, **73**:249-260.
57. Wang X, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Grompe M: **The origin and liver repopulating capacity of murine oval cells.** *Proc Natl Acad Sci U S A* 2003, **100** Suppl 1:11881-11888.
58. Gouon-Evans V, Boussemart L, Gadue P, Nierhoff D, Koehler CI, Kubo A, Shafritz DA, Keller G: **BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm.** *Nat Biotechnol* 2006, **24**:1402-1411.
59. Ren X, Hogaboam C, Carpenter A, Colletti L: **Stem cell factor restores hepatocyte proliferation in IL-6 knockout mice following 70% hepatectomy.** *J Clin Invest* 2003, **112**:1407-1418.
60. Koteish A, Diehl AM: **Animal models of steatosis.** *Semin Liver Dis* 2001, **21**:89-104.
61. Hensley ML, Ford JM: **Imatinib treatment: specific issues related to safety, fertility, and pregnancy.** *Semin Hematol* 2003, **40**:21-25.
62. EUMorphia: [<http://www.eumorphia.org>].
63. Herault Y, Beckers J, Kondo T, Fraudeau N, Duboule D: **Genetic analysis of a Hoxd-12 regulatory element reveals global versus local modes of controls in the HoxD complex.** *Development* 1998, **125**:1669-1677.
64. Boehler N, Riottot M, Ferezou J, Souidi M, Milliat F, Serougne C, Smith JL, Lutton C: **Antilithiasic effect of beta-cyclodextrin in LPN hamster: comparison with cholestyramine.** *J Lipid Res* 1999, **40**:726-734.
65. Chiang JY: **Bile acid regulation of gene expression: roles of nuclear hormone receptors.** *Endocr Rev* 2002, **23**:443-463.
66. Haas MJ, Reinacher D, Li JP, Wong NC, Mooradian AD: **Regulation of apoA1 gene expression with acidosis: requirement for a transcriptional repressor.** *J Mol Endocrinol* 2001, **27**:43-57.
67. Glickman RM, Rogers M, Glickman JN: **Apolipoprotein B synthesis by human liver and intestine in vitro.** *Proc Natl Acad Sci U S A* 1986, **83**:5296-5300.
68. Wang J, Olin M, Rozell B, Bjorkhem I, Einarsson C, Eggertsen G, Gafvels M: **Differential hepatocellular zonation pattern of cholesterol 7alpha-hydroxylase (Cyp7a1) and sterol 12alpha-hydroxylase (Cyp8b1) in the mouse.** *Histochem Cell Biol* 2007, **127**:253-261.
69. Geier A, Wagner M, Dietrich CG, Trauner M: **Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration.** *Biochim Biophys Acta* 2007, **1773**:283-308.
70. Meier PJ, Stieger B: **Bile salt transporters.** *Annu Rev Physiol* 2002, **64**:635-661.
71. Sehayek E, Wang R, Ono JG, Zinchuk VS, Duncan EM, Shefer S, Vance DE, Ananthanarayanan M, Chait BT, Breslow JL: **Localization of the PE methylation pathway and SR-BI to the canalicular membrane: evidence for apical PC biosynthesis that may promote biliary excretion of phospholipid and cholesterol.** *J Lipid Res* 2003, **44**:1605-1613.

72. Miquel JF, Moreno M, Amigo L, Molina H, Mardones P, Wistuba, Rigotti A: **Expression and regulation of scavenger receptor class B type I (SR-BI) in gall bladder epithelium.** *Gut* 2003, **52**:1017-1024.
73. Camps L, Reina M, Llobera M, Bengtsson-Olivecrona G, Olivecrona T, Vilaro S: **Lipoprotein lipase in lungs, spleen, and liver: synthesis and distribution.** *J Lipid Res* 1991, **32**:1877-1888.
74. Jin W, Broedl UC, Monajemi H, Glick JM, Rader DJ: **Lipase H, a new member of the triglyceride lipase family synthesized by the intestine.** *Genomics* 2002, **80**:268-273.
75. Gafvels ME, Paavola LG, Boyd CO, Nolan PM, Wittmaack F, Chawla A, Lazar MA, Bucan M, Angelin BO, Strauss JF 3rd: **Cloning of a complementary deoxyribonucleic acid encoding the murine homolog of the very low density lipoprotein/apolipoprotein-E receptor: expression pattern and assignment of the gene to mouse chromosome 19.** *Endocrinology* 1994, **135**:387-394.
76. Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL, Tall AR: **Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes.** *J Clin Invest* 1996, **98**:2373-2380.
77. Gordon DA, Wetterau JR, Gregg RE: **Microsomal triglyceride transfer protein: a protein complex required for the assembly of lipoprotein particles.** *Trends Cell Biol* 1995, **5**:317-321.
78. Wang X, Seed B: **A PCR primer bank for quantitative gene expression analysis 10.1093/nar/gng154.** *Nucl Acids Res* 2003, **31**:e154.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

